Omnipod® 5
Pod shown without necessary adhesive.
Omnipod 5 is the first and only automated insulin delivery (AID) system to be FDA-cleared for adults living with type 2 diabetes in the US!
Omnipod 5 offers simplicity, clinical results, and broad access so that you can offer your patients the technology that is right for them.
Omnipod 5 Demonstrated Improved Results for People Living with Type 2 Diabetes
The Omnipod 5 SECURE-T2D clinical study is the longest, largest, and most racially diverse clinical study of automated insulin delivery (AID) in type 2 diabetes completed to date.1
46%
of study participants were Black, Hispanic, or Latino2
55%
of study participants were using a GLP-12
84%
of study participants not carb-counting before enrollment2
- Lowered A1C regardless of patients’ race, ethnicity, GLP-1 use, and whether they were carb counting or not. In patients with a baseline of A1C ≥9%, the A1C was lowered by 2.1% (-0.8% in full study population)2
- More time in range by nearly 5 hours a day (% of time spent between 70-180 mg/dL)2
- No demonstrated increase in time in hypoglycemia (% time spent <70 mg/dL)2
- 29% reduction in insulin need2
One case of severe hypoglycemia was reported by an adult with type 2 diabetes during Omnipod 5 System use. The case was not related to Omnipod 5 System malfunction.
Interested in understanding the SECURE-T2D study in greater detail? Watch clinical investigators discuss results.
“Advancing Toward AID for All”
SECURE-T2D study excerpt by Dr. Francisco Pasquel from the Omnipod 5 Product Theater that was recorded at the American Diabetes Association’s 84th Scientific Sessions Meeting in Orlando, FL.
“Unlock the Future of Type 2 Diabetes Care”
Omnipod's Beyond the Bolus Podcast episode featuring Dr. Viral Shah.
Download the Omnipod 5 brochure, including a study overview.
SECURE-T2D Study Participants Had a High Level of Satisfaction with Omnipod 5
Participants in the Omnipod 5 SECURE-T2D study reported the following:
- Clinically meaningful reduction in diabetes distress2
- Simple bolusing—over 91% said it was easy to use the SmartBolus Calculator3
- 90% would recommend Omnipod 5 to a friend or family member3
- 72% said they barely noticed wearing the discreet, tubeless and waterproof4 system3
- Continued use—78% said that they would like to continue to use Omnipod 5 after the study3
“I am a nurse and know the importance of controlling my diabetes but unfortunately, I would miss my insulin injections … I was on a dangerous path.
With Omnipod 5, I have far fewer ups/downs of high and low sugars, and along with it, the terrible symptoms associated with that. Omnipod has been life changing for me.”5
—Milli, Omnipod 5 User with type 2 diabetes
Mili has an ongoing commercial relationship with Insulet.
Omnipod 5 Has Broad Access Through the Pharmacy
- The only AID system covered under Medicare Part D without a C-peptide test
- Simple pharmacy access means that patients can pick up Pods when they pick up their insulin
- A majority of Omnipod 5 users with type 2 diabetes pay less than $50 a month6
Ready to take the next steps?
Have questions about type 2 indication?
Want to learn more about
Omnipod 5?
Do you have patients who can benefit?
Subscribe to Stay in Touch
Our newsletter for healthcare providers includes the latest Omnipod news and educational resources.
1. Insulet data on file. August 2024. Based on presented clinical trials of the current AID landscape in T2D.
2. Pasquel FJ, et al. SECURE-T2D clinical study. Presented at: ADA; June 21-24, 2024; Orlando, FL. Subgroup analysis of 68 participants with baseline A1C ≥ 9% Mean HbA1c: standard therapy vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%). Mean time in range (70-180 mg/dL): standard therapy vs. 13-week Omnipod 5: 45% vs. 66%, P<0.001. Mean time <70 mg/dL as measured by CGM: standard therapy = 0.2%, 3-mo Omnipod 5 = 0.2%. Mean T2-DDAS total intensity score: standard therapy = 2.5, 3-mo Omnipod 5 = 2.2, P<0.001. Mean Proportion with T2-DDAS ≥ 2.0, no. (%): standard therapy = 66%; 3-mo Omnipod 5 = 55%, P<0.001
3. Insulet Data on File. SECURE-T2D Clinical Study Report. 2024.
4. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.
5. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Median time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Results measured by CGM. Study funded by Insulet.
Sherr JL, et al. Diabetes Care. 2022. 45(8):1907–1910. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.41%, 3-mo Omnipod 5 = 2.13%, P=0.0185. Results measured by CGM. Study funded by Insulet.
Pasquel FJ, et al. Presented at: ADA; June 21-24, 2024; Orlando, FL. Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase
6. Source: IQVIA OPCL. Majority is defined over 70%. Based on paid claims for Omnipod 5 G6 Pods with a type 2 diabetes diagnosis code. Includes commercial and Medicare claims January 2023 through December 2023.
INS-OHS-10-2024-00078 v1.0
2. Pasquel FJ, et al. SECURE-T2D clinical study. Presented at: ADA; June 21-24, 2024; Orlando, FL. Subgroup analysis of 68 participants with baseline A1C ≥ 9% Mean HbA1c: standard therapy vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%). Mean time in range (70-180 mg/dL): standard therapy vs. 13-week Omnipod 5: 45% vs. 66%, P<0.001. Mean time <70 mg/dL as measured by CGM: standard therapy = 0.2%, 3-mo Omnipod 5 = 0.2%. Mean T2-DDAS total intensity score: standard therapy = 2.5, 3-mo Omnipod 5 = 2.2, P<0.001. Mean Proportion with T2-DDAS ≥ 2.0, no. (%): standard therapy = 66%; 3-mo Omnipod 5 = 55%, P<0.001
3. Insulet Data on File. SECURE-T2D Clinical Study Report. 2024.
4. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.
5. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Median time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Results measured by CGM. Study funded by Insulet.
Sherr JL, et al. Diabetes Care. 2022. 45(8):1907–1910. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.41%, 3-mo Omnipod 5 = 2.13%, P=0.0185. Results measured by CGM. Study funded by Insulet.
Pasquel FJ, et al. Presented at: ADA; June 21-24, 2024; Orlando, FL. Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase
6. Source: IQVIA OPCL. Majority is defined over 70%. Based on paid claims for Omnipod 5 G6 Pods with a type 2 diabetes diagnosis code. Includes commercial and Medicare claims January 2023 through December 2023.
INS-OHS-10-2024-00078 v1.0